The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced Solid Tumor · Advanced Malignant Neoplasm · Metastatic Cancer · Metastatic Solid Tumor · Lung Cancer · Ovarian Cancer · Endometrial Cancer · Prostate Cancer · Colorectal Cancer · Breast Cancer · Other Cancer · Locally Advanced · Head and Neck Cancer · Gall Bladder Cancer · Small Cell Lung Cancer · Small Cell Lung Cancer ( SCLC ) · Small Cell Lung Carcinoma · NSCLC · NSCLC (Non-small Cell Lung Cancer) · SCLC · Non-Small Cell Lung Carcinoma · Triple Negative Breast Cancer · TNBC · HER2+ Breast Cancer · Non-Small Cell Lung Cancer · ER/PR Positive Breast Cancer · HER2- Breast Cancer · HER2-positive Breast Cancer · HER2-negative Breast Cancer · ER/PR(+), Her2(-) Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University of California Irvine Chao Family Comprehensive Cancer Center, Irvine, California, United States

  • University of San Diego Moores Cancer Center, La Jolla, California, United States

    Contact: Study coordinator (Shumei Kato, MD)
  • UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

    Contact: Study coordinator (Gottfried Konecny, MD)
  • USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

    Contact: Study coordinator (Anthony El-Khoueiry, MD)
  • Rocky Mountain Cancer Center, Denver, Colorado, United States

    Contact: Study coordinator (Allen Cohn, MD)
  • Yale Cancer Center, New Haven, Connecticut, United States

    Contact: Study coordinator (Patricia LoRusso, MD)
  • Medical Oncology Hematology Consultants, Newark, Delaware, United States

    Contact: Study coordinator (Jamal Misleh, MD)
  • University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States

    Contact: Study coordinator (Gilberto de Lima Lopes Jr., MD)
  • Advent Health, Orlando, Florida, United States

    Contact: Study coordinator (Robert Holloway, MD)
  • Florida Cancer Specialists South, Port Charlotte, Florida, United States

    Contact: Study coordinator (Ivor Percent, MD)
  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Aparna Parikh, MD)
  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Geoffrey Shapiro, MD, PhD)
  • Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Dipesh Uprety, MD)
  • University of Nebraska Medical Center Buffet Cancer Center, Omaha, Nebraska, United States

    Contact: Study coordinator (Lindsey McAlarnen, MD, M.Sc.)
  • Memorial Sloan Kettering, New York, New York, United States

    Contact: Study coordinator (Alison Schram, MD)
  • Duke University, Durham, North Carolina, United States

    Contact: Study coordinator (Niharika Mettu, MD, PhD)
  • The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

    Contact: Study coordinator (Dale Shepard, MD)
  • University of Oklahoma, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Debra Richardson, MD)
  • Oregon Health & Science University (OHSU), Portland, Oregon, United States

    Contact: Study coordinator (Shivaani Kummar, MD)
  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Lainie Martin, MD)
  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Sarah Taylor, MD, PhD)
  • WellSpan York Cancer Center, York, Pennsylvania, United States

    Contact: Study coordinator (Ikechukwu Akunyili, MD)
  • Medical University of South Carolina, Charleston, South Carolina, United States

  • Sarah Cannon Research Institute, Nashville, Tennessee, United States

    Contact: Study coordinator (Melissa Johnson, MD)
  • New Experimental Therapeutics - NEXT Oncology, Austin, Texas, United States

    Contact: Study coordinator (Anthony Tolcher, MD)
  • Texas Oncology, Bedford, Texas, United States

    Contact: Study coordinator (Terrence Wong, MD)
  • UTSW - Moody Outpatient Center - Parkland Health, Dallas, Texas, United States

    Contact: Study coordinator (David Miller, MD)
  • UT Southwest Simmons Cancer Center, Dallas, Texas, United States

    Contact: Study coordinator (David Miller, MD)
  • The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Ecaterina Dumbrava, MD)
  • New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio, Texas, United States

    Contact: Study coordinator (Anthony Tolcher, MD)
  • Virginia Cancer Specialists, Fairfax, Virginia, United States

    Contact: Study coordinator (Alexander Spira, MD)
  • University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Study coordinator (Andrew Coveler, MD)
  • University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

    Contact: Study coordinator (Nataliya Uboha, MD, PhD)
  • Chris O'Brien Lifehouse Hospital, Camperdown, New South Wales, Australia

    Contact: Study coordinator (Peter Grimison, MD)
  • Mater Cancer Care Centre, South Brisbane, Queensland, Australia

    Contact: Study coordinator (Catherine Shannon, MD)
  • Flinders Medical Center, Bedford Park, South Australia, Australia

    Contact: Study coordinator (Shwagi Sukumaran, MD)
  • Monash Medical Centre, Clayton, Victoria, Australia

    Contact: Study coordinator (Sophia Frentzas, MD)
  • Linear Clinical Research, Nedlands, Western Australia, Australia

    Contact: Study coordinator (Michael Millward, MD)
  • ICANS - Institut de cancérologie Strasbourg Europe, Strasbourg, Bas-Rhin, France

    Contact: Study coordinator (Lauriane Eberst, MD)
  • Institut Bergonie, Bordeaux, Gironde, France

    Contact: Study coordinator (Veronique Debien, MD)
  • Institut Claudius Regaud, Toulouse, Haute-Garonne, France

    Contact: Study coordinator (Carlos-Alberto Gomez-Roca, MD)
  • EDOG Institut de Cancerologie de l'Ouest, Saint-Herblain, Loire-Atlantique, France

    Contact: Study coordinator (Jean-Sebastien Frenel, MD)
  • Centre Jean Perrin, Clermont-Ferrand, Puy-de-Dôme, France

    Contact: Study coordinator (Xavier Durando, MD)
  • Institut Gustave Roussy, Villejuif, Val-de-Marne, France

    Contact: Study coordinator (Yohann Loriot, MD)
  • Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer, Lyon, France

    Contact: Study coordinator (Isabelle Ray-Coquard, MD)
  • CHU de Nîmes, Nîmes, France

    Contact: Study coordinator (Frédéric Fiteni, MD, PhD)
  • Institute Cancer De Lorraine, Vandœuvre-lès-Nancy, France

    Contact: Study coordinator (Aurélien Lambert, MD)
  • Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Baden-Wurttemberg, Germany

    Contact: Study coordinator (Martin Haag, MD)
  • Universitätsklinikum Augsburg, Augsburg, Bavaria, Germany

    Contact: Study coordinator (Rainer Claus, MD)
  • Asklepios Klinik Altona, Hamburg, Free and Hanseatic City of Hamburg, Germany

    Contact: Study coordinator (Dirk Arnold, MD)
  • Universitätsklinikum Frankfurt, Frankfurt am Main, Hesse, Germany

  • Universitätsklinikum Essen, Essen, North Rhine-Westphalia, Germany

    Contact: Study coordinator (Marcel Wiesweg, MD)
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio, Italy

    Contact: Study coordinator (Anna Fagotti, MD)
  • Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena, Rome, Lazio, Italy

    Contact: Study coordinator (Lorenza Landi, MD)
  • ASST Grande Ospedale Metropolitano Niguarda, Milan, Lombardy, Italy

    Contact: Study coordinator (Salvatore Siena, MD)
  • Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Lombardy, Italy

    Contact: Study coordinator (Massimo Di Nicola, MD)
  • Istituto Europeo Di Oncologia, Milan, Lombardy, Italy

    Contact: Study coordinator (Giuseppe Curigliano, MD)
  • Istituto Clinico Humanitas, Rozzano, Lombardy, Italy

    Contact: Study coordinator (Armando Santoro, MD)
  • Fondazione del Piemonte per l'Oncologia (IRCCS), Candiolo, Torino, Italy

    Contact: Study coordinator (Chiara Lazzari, MD)
  • Humanitas San Pio X, Milan, Italy

    Contact: Study coordinator (Domenica Lorusso, MD)
  • IRCCS - lstituto Nazionale Tumori - Fondazione G. Pascale, Naples, Italy

    Contact: Study coordinator (Anna Passarelli, MD)
  • National University Hospital, Kent Ridge, Singapore

    Contact: Study coordinator (David Shao Peng Tan, MD)
  • National Cancer Center of Singapore, Singapore, Singapore

    Contact: Study coordinator (Tira Tan, MD)
  • Asan Medical Center, Seoul, South Korea

    Contact: Study coordinator (Dae Ho Lee, MD)
  • National Cancer Center, Seoul, South Korea

    Contact: Study coordinator (Myong Cheol Lim, MD, PhD)
  • Samsung Medical Center, Seoul, South Korea

    Contact: Study coordinator (Chel Hun Choi, MD)
  • Seoul University Hospital, Seoul, South Korea

    Contact: Study coordinator (Seock-Ah Im, MD)
  • Severance Hospital Yonsei University, Seoul, South Korea

    Contact: Study coordinator (Jung-Yun Lee, MD)
  • START MADRID_Hospital Universitario Fundacion Jimenez Diaz, Madrid, Madrid, Spain

    Contact: Study coordinator (Victor Moreno Garcia, MD)
  • START MADRID_Hospital Universitario HM Sanchinarro - CIOCC, Madrid, Madrid, Spain

    Contact: Study coordinator (Irene Moreno, MD)
  • Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON, Barcelona, Spain

    Contact: Study coordinator (Lorena Farinas, MD)
  • NEXT Oncology-Hospital Quironsalud Barcelona, Barcelona, Spain

    Contact: Study coordinator (Elena Garralda, MD)
  • Hospital Universitario 12 de Octubre, Madrid, Spain

    Contact: Study coordinator (Santiago Ponce Aix, MD)
  • START Rioja, Rioja, Spain

    Contact: Study coordinator (Maria de Miguel Luken, MD)
  • Hospital Clinico Universitario de Valencia, Valencia, Spain

    Contact: Study coordinator (José Alejandro Pérez Fidalgo, MD)
  • Sarah Cannon Research Institute UK, London, Middlesex, United Kingdom

    Contact: Study coordinator (Elisa Fontana, MD, PhD)
  • Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom

    Contact: Study coordinator (Alastair Greystoke, MB ChB PhD)
Study leads
  • Marc Fellous, MD

    Study Director

    Sr. Vice President of Medical Affairs